Capvaxive approved for children at high risk for pneumococcal disease

The FDA has expanded the approval of Merck’s 21-valent pneumococcal vaccine to include children at increased risk for pneumococcal disease, the drug maker announced Thursday. Capvaxive (PCV21), which was initially approved for adults in 2024, is now also approved for children and teens aged 2 through 17 years who have completed a primary pediatric pneumococcal vaccine series but remain at

Raccontata dahealio.commorningstar.combenzinga.com